The Neuroscience Institute conducts clinical trials in conjunction with pharmaceutical companies and members of our clinical faculty. We are also a NeuroNext site, which is a clinical trials consortium that links clinical trials in rare neurological diseases across the country.
A number of clinical trials are currently underway in areas such as:
- Controlling Lennox-Gastaut syndrome with anti-epileptic drugs
- Outcomes of children with solitary calvarial (skull) eosinophilic granuloma
- Neuron loss for children with significant brain injury
- Testosterone therapy in early adolescents with Klinefelter syndrome
- Treatment medication for children with Fragile X syndrome
- Refractory complex partial seizures and epilepsy in children
- Timing of giving medication during shunt and spine surgeries
- Treatment of children and young adults with newly diagnosed diffuse intrinsic tumors
For additional information on our clinical trials, please email NSIresearch@childrenscolorado.org or visit ClinicalTrials.gov.
In addition to clinical trials, researchers at the Neuroscience Institute collaborate on international and national clinical studies. Because our doctors see a large volume of children and treat complex cases, they have a unique opportunity to conduct clinical research on a broad range of neurological subspecialties.
Our clinical research studies look at:
Clinical research in pediatric epilepsy includes participation in National Institute of Health (NIH) and other consortiums, therapeutic trials, and outcome studies related to epilepsy syndromes, epilepsy surgery, tuberous sclerosis, and the ketogenic diet. Examples include studying infantile spasms treatment strategies, genetic markers in patients treated with adrenocorticotropic hormone (ACTH), the use of EEGs in investigating traumatic brain injuries, and biomarkers associated with focal epilepsy disease progression.